Clinical Trials Logo

Oligodendroglioma clinical trials

View clinical trials related to Oligodendroglioma.

Filter by:

NCT ID: NCT01148966 Terminated - Adult Glioblastoma Clinical Trials

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors. Aminolevulinic acid becomes active when it is exposed to a certain kind of light and may help doctors find and remove tumor cells during surgery

NCT ID: NCT01103375 Terminated - Adult Glioblastoma Clinical Trials

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given with isotretinoin in treating patients with recurrent malignant glioma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help cells that are involved in the body's immune response to work better. Giving erlotinib hydrochloride together with isotretinoin may kill more tumor cells

NCT ID: NCT01095094 Terminated - Glioblastoma Clinical Trials

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Start date: January 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ritonavir together with lopinavir works in treating patients with progressive or recurrent high-grade glioma.

NCT ID: NCT01088763 Terminated - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00897377 Terminated - Oligoastrocytoma Clinical Trials

Treatment Strategy for Low-grade Gliomas

Start date: December 2007
Phase: Phase 3
Study type: Interventional

Although the prognosis of patients with low-grade glioma (LGG) is generally good, recurrence seems unavoidable in some patients because of the infiltrative growth of the tumors. How to treat LGGs is still under controversy. The role of radiation therapy and chemotherapy in the treatment of LGG need to be further investigated. The purpose of this study is the following: 1. to investigate the role of early radiation therapy in MRI-determined total resected LGGs; 2. to compare the efficacy of early radiation therapy and that of initial chemotherapy in the LGGs without total resection.

NCT ID: NCT00430079 Terminated - Adult Glioblastoma Clinical Trials

Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma

Start date: July 2001
Phase: N/A
Study type: Interventional

This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma. Diagnostic procedures using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment

NCT ID: NCT00389090 Terminated - Glioma Clinical Trials

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Start date: October 2006
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.

NCT ID: NCT00360828 Terminated - Glioma Clinical Trials

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Start date: February 2006
Phase: Phase 2
Study type: Interventional

Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects.

NCT ID: NCT00110032 Terminated - Adult Glioblastoma Clinical Trials

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

Start date: June 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment

NCT ID: NCT00062504 Terminated - Clinical trials for Glioblastoma Multiforme

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Start date: July 2003
Phase: Phase 2
Study type: Interventional

To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.